Comparing Artiva Biotherapeutics (ARTV) & Its Rivals

Artiva Biotherapeutics (NASDAQ:ARTV) is one of 616 publicly-traded companies in the “MED – BIOMED/GENE” industry, but how does it contrast to its rivals? We will compare Artiva Biotherapeutics to related businesses based on the strength of its risk, institutional ownership, dividends, valuation, analyst recommendations, earnings and profitability.

Risk and Volatility

Artiva Biotherapeutics has a beta of 2.92, suggesting that its stock price is 192% more volatile than the S&P 500. Comparatively, Artiva Biotherapeutics’ rivals have a beta of 1.03, suggesting that their average stock price is 3% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Artiva Biotherapeutics and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1	0	4	1	2.83
Artiva Biotherapeutics Competitors	7412	12757	38846	1251	2.56

Artiva Biotherapeutics presently has a consensus price target of $19.00, indicating a potential upside of 375.00%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 64.30%. Given Artiva Biotherapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Artiva Biotherapeutics is more favorable than its rivals.

Institutional and Insider Ownership

51.3% of shares of all “MED – BIOMED/GENE” companies are held by institutional investors. 21.4% of Artiva Biotherapeutics shares are held by company insiders. Comparatively, 13.2% of shares of all “MED – BIOMED/GENE” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Artiva Biotherapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-49.99%	-44.05%
Artiva Biotherapeutics Competitors	-910.50%	-116.60%	-28.78%

Earnings and Valuation

This table compares Artiva Biotherapeutics and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Artiva Biotherapeutics	$250,000.00	-$65.37 million	-1.55
Artiva Biotherapeutics Competitors	$994.30 million	$76.94 million	8.08

Artiva Biotherapeutics’ rivals have higher revenue and earnings than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Artiva Biotherapeutics beats its rivals on 8 of the 13 factors compared.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.